Related references
Note: Only part of the references are listed.TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts
Vincenzo Damiano et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Ligand-induced conformational changes allosterically activate Toll-like receptor 9
Eicke Latz et al.
NATURE IMMUNOLOGY (2007)
Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients
Barbara G. Molenkamp et al.
CLINICAL CANCER RESEARCH (2007)
Development of TLR9 agonists for cancer therapy
Arthur M. Krieg
JOURNAL OF CLINICAL INVESTIGATION (2007)
Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9
Maria C. Lebre et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2007)
Phase II trial of a Toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma
Mikhail Pashenkov et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells
Jongdae Lee et al.
NATURE CELL BIOLOGY (2006)
The adaptor molecule MyD88 activates PI-3 kinase signaling in CD4+ T cells and enables CpG oligodeoxynucleotide-mediated costimulation
Andrew E. Gelman et al.
IMMUNITY (2006)
Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma
Brian K. Link et al.
JOURNAL OF IMMUNOTHERAPY (2006)
New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site
Victor Appay et al.
JOURNAL OF IMMUNOLOGY (2006)
Pathogen recognition and innate immunity
S Akira et al.
CELL (2006)
Novel Toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors
V Damiano et al.
CLINICAL CANCER RESEARCH (2006)
Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma
A Carpentier et al.
NEURO-ONCOLOGY (2006)
Therapeutic potential of Toll-like receptor 9 activation
Arthur M. Krieg
NATURE REVIEWS DRUG DISCOVERY (2006)
Expression of Toll-like receptor 9 and response to bacterial CpG oligodeoxynucleotides in human intestinal epithelium
G Pedersen et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2005)
Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909
DE Speiser et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells
B Jahrsdörfer et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2005)
IFN-α regulates TLR-dependent gene expression of IFN-α, IFN-β, IL-28, and IL-29
J Sirén et al.
JOURNAL OF IMMUNOLOGY (2005)
Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma:: increased interferon-α/β-inducible gene expression, without significant toxicity
JW Friedberg et al.
BLOOD (2005)
Human lung cancer cells express functionally active Toll-like receptor 9
D Droemann et al.
RESPIRATORY RESEARCH (2005)
Prognosis of premenopausal breast cancer and childbirth prior to diagnosis
KA Phillips et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death:: A study from the acute leukemia working party of the European Group for Blood and Marrow Transplantation
O Ringdén et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Toll-like receptor control of the adaptive immune responses
A Iwasaki et al.
NATURE IMMUNOLOGY (2004)
CpG DNA-mediated immune response in pulmonary endothelial cells
J Li et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2004)
CpG oligodeoxynucleotide enhances tumor response to radiation
L Milas et al.
CANCER RESEARCH (2004)
Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15
M Wysocka et al.
BLOOD (2004)
Human monocytes infected with Yersinia pestis express cell surface TLR9 and differentiate into dendritic cells
KU Saikh et al.
JOURNAL OF IMMUNOLOGY (2004)
Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors
P Daftarian et al.
CANCER RESEARCH (2004)
Microbial DNA induces a host defense reaction of human respiratory epithelial cells
J Platz et al.
JOURNAL OF IMMUNOLOGY (2004)
Toll-like receptors stimulate human neutrophil function
F Hayashi et al.
BLOOD (2003)
Pros and cons of adjuvant interferon in the treatment of melanoma
MS Sabel et al.
ONCOLOGIST (2003)
FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging
C Franzius et al.
ANNALS OF ONCOLOGY (2002)
Share Paper
